Corcept Therapeutics Launches Website Supporting Phase 3 Trial of Relacorilant in Patients With Cushing’s Syndrome

MENLO PARK, Calif. (March 23, 2019) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol, today announced a new website to support recruitment in the Phase 3 trial (known as “GRACE”) of Corcept’s proprietary compound, relacorilant, to treat patients with Cushing’s syndrome. The website,, matches interested patients to nearby study sites.

Continue Reading


More Articles ...

Available Now!

PPRG6-500 Cover
The Pituitary Patient Resource Guide Sixth Edition is now available! Be one of the first to have the most up-to-date information. The Pituitary Patient Resource Guide a one of a kind publication intended as an invaluable source of information not only for patients but also their families, physicians, and all health care providers. It contains information on symptoms, proper testing, how to get a diagnosis, and the treatment options that are available. It also includes Pituitary Network Association's patient resource listings for expert medical care.

Buy Now